OBJECTIVE： To investigate therapeutic efficacy and safety of edaravone and nimodipine in the treatment of acute large area cerebral infarction. METHODS： 101 patients with acute large area cerebral infarction were analyzed retrospectively and divided into control group （53 cases） and observation group （48 cases） according to drug use. After admission， control group received routine treatment as relieving cerebral edema， anticoagulant and antiplatelet agglutination. Observation group was additionally given Edaravone injection 30 mg added into 0.9％ Sodium chloride injection 100 mL intravenously， within 30 min， twice a day+Nimodipine injection 12 mg added into 0.9％ Sodium chloride injection 500 mL intravenously， once a day， at dripping speed of 0.5μg/（kg·min）， for 10 days， and then given Nimodipine tablet 60 mg orally instead， 3 times a day， for 5 d， on the basis of control group. Treatment course of 2 groups lasted for 15 d. Clinical efficacies of 2 groups were observed as well as SpO2， hemoglobin （Hb）， total hemoglobin （HBT）， reduced hemoglobin （MHb）， NIHSS score and the occurrence of ADR before and after treatment. RESULTS： Total response rate of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the levels of SpO2， Hb， HBT， MHb and NIHSS score between 2 groups （P＞0.05）. After treatment， the levels of SpO2， HBT and MHb in 2 groups were significantly higher than before， and the observation group was significantly higher than the control group； NIHSS score of 2 groups were significantly lower than before， and the observation group was significantly lower than the control group； Hb level of 2 groups were significantly lower than before， with statistical significance （P＜0.05）， but there was no statistical significance in Hb level between 2 groups （P＞0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： On the basis of conventional therapy， edaravone combined with nimodipine in the treatment of acute large area cerebral infarction has significant therapeutic efficacy， can improve neurological impairment， but doesn’t increase the occurrence of ADR.